Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.230
-0.060 (-4.65%)
At close: Mar 3, 2026, 4:00 PM EST
1.250
+0.020 (1.63%)
After-hours: Mar 3, 2026, 7:13 PM EST
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,651,686
Market Cap
5.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2023 | 10 | 4 | 66.67% | 9 | 1 |
| Dec 31, 2022 | 6 | - | - | 6 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| BiomX | 57 |
| Calidi Biotherapeutics | 28 |
| VivoSim Labs | 14 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 9 |
| Aprea Therapeutics | 8 |
| Immuron | 7 |
| Can-Fite BioPharma | 5 |
REVB News
- 5 days ago - Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 - Accesswire
- 5 weeks ago - Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 - Accesswire
- 5 weeks ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Accesswire
- 5 weeks ago - Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - Accesswire
- 6 weeks ago - Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - Accesswire
- 7 weeks ago - Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Accesswire
- 7 weeks ago - Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - Accesswire
- 3 months ago - Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting - Accesswire